Technical Analysis for EYPT - EyePoint Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 1.78 -3.78% -0.07
EYPT closed down 4.32 percent on Monday, May 20, 2019, on 43 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical EYPT trend table...

Date Alert Name Type % Chg
Bearish Engulfing Bearish 0.56%
Stochastic Sell Signal Bearish 0.56%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.56%
Bollinger Band Squeeze Range Contraction 0.56%
Weak + Overbought Other 0.56%
BB Squeeze + Upper Band Touch Range Contraction 0.56%
Weak, Overbought and Reversal Signs Reversal 0.56%
Overbought Stochastic Strength 0.56%
Upper Bollinger Band Touch Strength 0.56%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.78%

Older signals for EYPT ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials. It also offers Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis. In addition, the company has developed DEXYCU (dexamethasone intraocular suspension), an intraocular product for the treatment of postoperative ocular inflammation; and Vitrasert (ganciclovir), a sustained release implant for the treatment of cytomegalovirus retinitis. Further, it develops YUTIQ shorter-actinguveitis for the treatment of posterior segment uveitis; and Durasert tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration. Additionally, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It sells its products primarily in the United States and Europe. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, and Enigma Therapeutics Limited. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.
Medicine Chemistry Biopharmaceutical Organic Compounds Technology Platforms Wet Age Related Macular Degeneration Glucocorticoids Macular Edema Ophthalmic Products Uveitis Chronic Diseases Diabetic Macular Edema Eye Diseases Pregnanes Alimera Sciences Cytomegalovirus Retinitis Diketones Diols
Is EYPT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.94
52 Week Low 1.24
Average Volume 456,156
200-Day Moving Average 2.2668
50-Day Moving Average 1.9099
20-Day Moving Average 1.7265
10-Day Moving Average 1.741
Average True Range 0.1202
ADX 22.23
+DI 16.1827
-DI 16.0461
Chandelier Exit (Long, 3 ATRs ) 1.5094
Chandelier Exit (Short, 3 ATRs ) 1.7906
Upper Bollinger Band 1.8626
Lower Bollinger Band 1.5904
Percent B (%b) 0.66
BandWidth 15.766001
MACD Line -0.0184
MACD Signal Line -0.0506
MACD Histogram 0.0322
Fundamentals Value
Market Cap 69.68 Million
Num Shares 39.4 Million
EPS -0.52
Price-to-Earnings (P/E) Ratio -3.40
Price-to-Sales 6.21
Price-to-Book 3.51
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.94
Resistance 3 (R3) 1.95 1.91 1.91
Resistance 2 (R2) 1.91 1.87 1.90 1.90
Resistance 1 (R1) 1.84 1.84 1.82 1.83 1.89
Pivot Point 1.80 1.80 1.79 1.79 1.80
Support 1 (S1) 1.73 1.76 1.71 1.72 1.65
Support 2 (S2) 1.69 1.73 1.68 1.64
Support 3 (S3) 1.62 1.69 1.63
Support 4 (S4) 1.61